New insight in immunotherapy and combine therapy in colorectal cancer
The advent of immune checkpoint inhibitors (ICIs) in colorectal cancer (CRC) treatment marks a major breakthrough. These therapies have proven safer and more effective than traditional radiotherapy and targeted treatments. Immunotherapies like pembrolizumab, nivolumab, and ipilimumab have pioneered...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Cell and Developmental Biology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcell.2024.1453630/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841556762961903616 |
|---|---|
| author | Kai Ji Kai Ji Hang Jia Zixuan Liu Guanyu Yu Rongbo Wen Tianshuai Zhang Zhiying Peng Wenjiang Man Wenjiang Man Yucheng Tian Yucheng Tian Can Wang Can Wang Qianlong Ling Wei Zhang Leqi Zhou Mulin Liu Bing Zhu |
| author_facet | Kai Ji Kai Ji Hang Jia Zixuan Liu Guanyu Yu Rongbo Wen Tianshuai Zhang Zhiying Peng Wenjiang Man Wenjiang Man Yucheng Tian Yucheng Tian Can Wang Can Wang Qianlong Ling Wei Zhang Leqi Zhou Mulin Liu Bing Zhu |
| author_sort | Kai Ji |
| collection | DOAJ |
| description | The advent of immune checkpoint inhibitors (ICIs) in colorectal cancer (CRC) treatment marks a major breakthrough. These therapies have proven safer and more effective than traditional radiotherapy and targeted treatments. Immunotherapies like pembrolizumab, nivolumab, and ipilimumab have pioneered new treatment avenues, potentially improving patient outcomes and quality of life. Additionally, advances in immunotherapy have prompted detailed research into CRC therapies, especially those integrating ICIs with conventional treatments, providing new hope for patients and shaping future research and practice. This review delves into the mechanisms of various ICIs and evaluates their therapeutic potential when combined with radiotherapy, chemotherapy, and targeted therapies in clinical settings. It also sheds light on the current application and research involving ICIs in CRC treatment. |
| format | Article |
| id | doaj-art-f653e3a4f6274a2ab1b4d0bd32d1a0e5 |
| institution | Kabale University |
| issn | 2296-634X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cell and Developmental Biology |
| spelling | doaj-art-f653e3a4f6274a2ab1b4d0bd32d1a0e52025-01-07T06:42:45ZengFrontiers Media S.A.Frontiers in Cell and Developmental Biology2296-634X2025-01-011210.3389/fcell.2024.14536301453630New insight in immunotherapy and combine therapy in colorectal cancerKai Ji0Kai Ji1Hang Jia2Zixuan Liu3Guanyu Yu4Rongbo Wen5Tianshuai Zhang6Zhiying Peng7Wenjiang Man8Wenjiang Man9Yucheng Tian10Yucheng Tian11Can Wang12Can Wang13Qianlong Ling14Wei Zhang15Leqi Zhou16Mulin Liu17Bing Zhu18Department of Gastrointestinal Surgery, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, ChinaDepartment of Colorectal Surgery, Shanghai Changhai Hospital, Naval Medical University, Shanghai, ChinaDepartment of Colorectal Surgery, Shanghai Changhai Hospital, Naval Medical University, Shanghai, ChinaDepartment of Colorectal Surgery, Shanghai Changhai Hospital, Naval Medical University, Shanghai, ChinaDepartment of Colorectal Surgery, Shanghai Changhai Hospital, Naval Medical University, Shanghai, ChinaDepartment of Colorectal Surgery, Shanghai Changhai Hospital, Naval Medical University, Shanghai, ChinaDepartment of Colorectal Surgery, Shanghai Changhai Hospital, Naval Medical University, Shanghai, ChinaDepartment of Colorectal Surgery, Shanghai Changhai Hospital, Naval Medical University, Shanghai, ChinaDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, ChinaDepartment of Colorectal Surgery, Shanghai Changhai Hospital, Naval Medical University, Shanghai, ChinaDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, ChinaDepartment of Colorectal Surgery, Shanghai Changhai Hospital, Naval Medical University, Shanghai, ChinaDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, ChinaDepartment of Colorectal Surgery, Shanghai Changhai Hospital, Naval Medical University, Shanghai, ChinaDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, ChinaDepartment of Colorectal Surgery, Shanghai Changhai Hospital, Naval Medical University, Shanghai, ChinaDepartment of Colorectal Surgery, Shanghai Changhai Hospital, Naval Medical University, Shanghai, ChinaDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, ChinaDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, ChinaThe advent of immune checkpoint inhibitors (ICIs) in colorectal cancer (CRC) treatment marks a major breakthrough. These therapies have proven safer and more effective than traditional radiotherapy and targeted treatments. Immunotherapies like pembrolizumab, nivolumab, and ipilimumab have pioneered new treatment avenues, potentially improving patient outcomes and quality of life. Additionally, advances in immunotherapy have prompted detailed research into CRC therapies, especially those integrating ICIs with conventional treatments, providing new hope for patients and shaping future research and practice. This review delves into the mechanisms of various ICIs and evaluates their therapeutic potential when combined with radiotherapy, chemotherapy, and targeted therapies in clinical settings. It also sheds light on the current application and research involving ICIs in CRC treatment.https://www.frontiersin.org/articles/10.3389/fcell.2024.1453630/fullimmunomodulatoryICISradiotherapychemotherapycombination therapycolorectal cancer |
| spellingShingle | Kai Ji Kai Ji Hang Jia Zixuan Liu Guanyu Yu Rongbo Wen Tianshuai Zhang Zhiying Peng Wenjiang Man Wenjiang Man Yucheng Tian Yucheng Tian Can Wang Can Wang Qianlong Ling Wei Zhang Leqi Zhou Mulin Liu Bing Zhu New insight in immunotherapy and combine therapy in colorectal cancer Frontiers in Cell and Developmental Biology immunomodulatory ICIS radiotherapy chemotherapy combination therapy colorectal cancer |
| title | New insight in immunotherapy and combine therapy in colorectal cancer |
| title_full | New insight in immunotherapy and combine therapy in colorectal cancer |
| title_fullStr | New insight in immunotherapy and combine therapy in colorectal cancer |
| title_full_unstemmed | New insight in immunotherapy and combine therapy in colorectal cancer |
| title_short | New insight in immunotherapy and combine therapy in colorectal cancer |
| title_sort | new insight in immunotherapy and combine therapy in colorectal cancer |
| topic | immunomodulatory ICIS radiotherapy chemotherapy combination therapy colorectal cancer |
| url | https://www.frontiersin.org/articles/10.3389/fcell.2024.1453630/full |
| work_keys_str_mv | AT kaiji newinsightinimmunotherapyandcombinetherapyincolorectalcancer AT kaiji newinsightinimmunotherapyandcombinetherapyincolorectalcancer AT hangjia newinsightinimmunotherapyandcombinetherapyincolorectalcancer AT zixuanliu newinsightinimmunotherapyandcombinetherapyincolorectalcancer AT guanyuyu newinsightinimmunotherapyandcombinetherapyincolorectalcancer AT rongbowen newinsightinimmunotherapyandcombinetherapyincolorectalcancer AT tianshuaizhang newinsightinimmunotherapyandcombinetherapyincolorectalcancer AT zhiyingpeng newinsightinimmunotherapyandcombinetherapyincolorectalcancer AT wenjiangman newinsightinimmunotherapyandcombinetherapyincolorectalcancer AT wenjiangman newinsightinimmunotherapyandcombinetherapyincolorectalcancer AT yuchengtian newinsightinimmunotherapyandcombinetherapyincolorectalcancer AT yuchengtian newinsightinimmunotherapyandcombinetherapyincolorectalcancer AT canwang newinsightinimmunotherapyandcombinetherapyincolorectalcancer AT canwang newinsightinimmunotherapyandcombinetherapyincolorectalcancer AT qianlongling newinsightinimmunotherapyandcombinetherapyincolorectalcancer AT weizhang newinsightinimmunotherapyandcombinetherapyincolorectalcancer AT leqizhou newinsightinimmunotherapyandcombinetherapyincolorectalcancer AT mulinliu newinsightinimmunotherapyandcombinetherapyincolorectalcancer AT bingzhu newinsightinimmunotherapyandcombinetherapyincolorectalcancer |